Cryoport (CYRX) Expected to Announce Earnings on Tuesday

Cryoport (NASDAQ:CYRX) is projected to post its quarterly earnings results after the market closes on Tuesday, March 4th. Analysts expect Cryoport to post earnings of ($0.33) per share and revenue of $58.71 million for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Cryoport Price Performance

NASDAQ CYRX opened at $6.33 on Tuesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32. The stock’s fifty day moving average price is $7.62 and its 200 day moving average price is $7.75. Cryoport has a 1 year low of $5.32 and a 1 year high of $20.10. The company has a market cap of $312.90 million, a price-to-earnings ratio of -1.87 and a beta of 1.59.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on CYRX shares. Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of Cryoport in a research report on Friday, January 17th. Roth Mkm cut their target price on Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. Finally, Guggenheim started coverage on Cryoport in a research report on Thursday, December 19th. They issued a “buy” rating and a $11.00 target price on the stock. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $12.29.

Insider Activity

In other news, Director Ramkumar Mandalam sold 7,369 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $7.46, for a total transaction of $54,972.74. Following the sale, the director now directly owns 59,497 shares in the company, valued at $443,847.62. This trade represents a 11.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 10.10% of the company’s stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.